News for iNtRON Biotechnology, Inc. (048530.KQ)

iNtRON Biotechnology, Inc. announced that New Drug Part has secured a potent anti-cancer candidate, PHAGERIA®, with broad antimicrobial activity against ETBF , a harmful microbe associated with...

/PRNewswire/ -- iNtRON Biotechnology ("iNtRON", www.intodeworld.com) has announced today that its New Drug Part has entered into an official contract with the...

/PRNewswire/ -- iNtRON Biotechnology ("iNtRON", www.intodeworld.com) has announced today the identification of Prophage and (non-) ORF-Jamphage from the...

/PRNewswire/ -- iNtRON Biotechnology ("iNtRON", www.intodeworld.com) has announced today that iNtRON has demonstrated the effectiveness of P18-BE3CRC using a...

/PRNewswire/ -- iNtRON Biotechnology ("iNtRON", www.intodeworld.com) has announced today that it has completed the efficacy evaluation study of BAL200, a novel...

/PRNewswire/ -- iNtRON Biotechnology ("iNtRON", www.intodeworld.com) has announced today that the Tech Transfer process of SAL200, endolysin-based new...

/PRNewswire/ -- iNtRON Biotechnology ("iNtRON", www.intodeworld.com) has announced today that the Company has established the 2nd generation technology of...

/PRNewswire/ -- iNtRON Biotechnology ("iNtRON", www.intodeworld.com) announced today that iNtRON has developed its unique CRISPR/Cas system customized for the...

/PRNewswire/ -- iNtRON Biotechnology ("iNtRON", www.intodeworld.com) announced today that CDL200, a novel biological drug candidate under the development of...

/PRNewswire/ -- iNtRON Biotechnology ("iNtRON" or "Company") announced today that the company has successfully completed the GLP toxicology studies of BAL200....